MX2021002882A - Focalizacion de egln1 en el cancer. - Google Patents

Focalizacion de egln1 en el cancer.

Info

Publication number
MX2021002882A
MX2021002882A MX2021002882A MX2021002882A MX2021002882A MX 2021002882 A MX2021002882 A MX 2021002882A MX 2021002882 A MX2021002882 A MX 2021002882A MX 2021002882 A MX2021002882 A MX 2021002882A MX 2021002882 A MX2021002882 A MX 2021002882A
Authority
MX
Mexico
Prior art keywords
egln1
cancer
targeting
dependent
vhl
Prior art date
Application number
MX2021002882A
Other languages
English (en)
Inventor
Francisca Vazquez
William Hahn
Colles Price
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of MX2021002882A publication Critical patent/MX2021002882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11029—Hypoxia-inducible factor-proline dioxygenase (1.14.11.29)

Abstract

La presente invención se refiere a composiciones y métodos para el diagnóstico y tratamiento o prevención de cánceres dependientes de EGLN1. En particular, la presente descripción proporciona identificación de un cáncer como dependiente de EGLN1, y la selección y/o administración de un inhibidor de EGLN1 o VHL (Supresor del Tumor de Von Hippel-Lindau) como un agente terapéutico para tal cáncer y/o un sujeto que tiene o está en riesgo de desarrollar tal cáncer.
MX2021002882A 2018-09-12 2019-09-11 Focalizacion de egln1 en el cancer. MX2021002882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730315P 2018-09-12 2018-09-12
PCT/US2019/050516 WO2020055946A1 (en) 2018-09-12 2019-09-11 Targeting egln1 in cancer

Publications (1)

Publication Number Publication Date
MX2021002882A true MX2021002882A (es) 2021-07-16

Family

ID=69776551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002882A MX2021002882A (es) 2018-09-12 2019-09-11 Focalizacion de egln1 en el cancer.

Country Status (4)

Country Link
US (1) US20220090083A1 (es)
EP (1) EP3850100A4 (es)
MX (1) MX2021002882A (es)
WO (1) WO2020055946A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516141A (zh) * 2020-12-07 2021-03-19 浙江大学 Cd47表达抑制剂及其与免疫治疗药物联合使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
US9193973B2 (en) 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
EP2957571B1 (en) 2014-06-17 2018-08-15 Centre National De La Recherche Scientifique (Cnrs) Monoclonal anti-pvhl antibodies and uses thereof

Also Published As

Publication number Publication date
WO2020055946A1 (en) 2020-03-19
EP3850100A4 (en) 2022-05-18
US20220090083A1 (en) 2022-03-24
EP3850100A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2021003389A (es) Metodos para tratar el cancer.
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2019011148A (es) Metodos de tratamiento.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2022008868A (es) Tratamiento del cancer con tg02.
SG10201902664RA (en) Combination therapy for treating cancer
ZA201907225B (en) Treatment of her2 positive cancers
NZ754865A (en) Combination therapy for the treatment of cancer
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020013120A (es) Tratamiento terapéutico de cánceres de microsatélites inestables.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2021003262A (es) Metodos de tratamiento.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2021002882A (es) Focalizacion de egln1 en el cancer.
MX2019001545A (es) Composiciones y metodos para tratar cancer con supresion de arginina y agentes de inmuno-oncologia.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2021003265A (es) Metodos de tratamiento.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.